よむ、つかう、まなぶ。
総－５参考５ (13 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_74036.html |
| 出典情報 | 中央社会保険医療協議会 総会（第651回 6／24）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
参考文献
1
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of
nonalcoholic fatty liver disease demonstrates an exponential increase in burden of
disease. Hepatology. 2018;67(1):123-33.
2
Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, et al. American
Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis
and Management of Nonalcoholic Fatty Liver Disease in Primary Care and
Endocrinology Clinical Settings: Co-Sponsored by the American Association for
the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528-62.
3
Parthasarathy
G,
Revelo
X,
Malhi
H.
Pathogenesis
of
Nonalcoholic
Steatohepatitis: An Overview. Hepatol Commun. 2020;4(4):478-92.
4
Alon L, Corica B, Raparelli V, Cangemi R, Basili S, Proietti M, et al. Risk of
cardiovascular events in patients with non-alcoholic fatty liver disease: a
systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29(6):938-46.
5
Calzadilla Bertot L, Adams LA. The Natural Course of Non-Alcoholic Fatty Liver
Disease. Int J Mol Sci. 2016;17(5).
6
McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of
NAFLD progression from steatosis to fibrosing-steatohepatitis using paired
biopsies: implications for prognosis and clinical management. J Hepatol.
2015;62(5):1148-55.
7
Banini BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease: Epidemiology,
Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. Clin
Med Insights Ther. 2016;8:75-84.
8
Horn CL, Morales AL, Savard C, Farrell GC, Ioannou GN. Role of CholesterolAssociated Steatohepatitis in the Development of NASH. Hepatol Commun.
2022;6(1):12-35.
9
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global
burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat
Rev Gastroenterol Hepatol. 2018;15(1):11-20.
10
Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a
metabolic disease in humans: A literature review. Diabetes Obes Metab.
2021;23(5):1069-83.
11
Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, et al. Glucagonlike peptide 1 (GLP-1). Mol Metab. 2019;30:72-130.
12
Targher G, Mantovani A, Byrne CD. Mechanisms and possible hepatoprotective
effects of glucagon-like peptide-1 receptor agonists and other incretin receptor
12
1
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of
nonalcoholic fatty liver disease demonstrates an exponential increase in burden of
disease. Hepatology. 2018;67(1):123-33.
2
Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, et al. American
Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis
and Management of Nonalcoholic Fatty Liver Disease in Primary Care and
Endocrinology Clinical Settings: Co-Sponsored by the American Association for
the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528-62.
3
Parthasarathy
G,
Revelo
X,
Malhi
H.
Pathogenesis
of
Nonalcoholic
Steatohepatitis: An Overview. Hepatol Commun. 2020;4(4):478-92.
4
Alon L, Corica B, Raparelli V, Cangemi R, Basili S, Proietti M, et al. Risk of
cardiovascular events in patients with non-alcoholic fatty liver disease: a
systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29(6):938-46.
5
Calzadilla Bertot L, Adams LA. The Natural Course of Non-Alcoholic Fatty Liver
Disease. Int J Mol Sci. 2016;17(5).
6
McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of
NAFLD progression from steatosis to fibrosing-steatohepatitis using paired
biopsies: implications for prognosis and clinical management. J Hepatol.
2015;62(5):1148-55.
7
Banini BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease: Epidemiology,
Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. Clin
Med Insights Ther. 2016;8:75-84.
8
Horn CL, Morales AL, Savard C, Farrell GC, Ioannou GN. Role of CholesterolAssociated Steatohepatitis in the Development of NASH. Hepatol Commun.
2022;6(1):12-35.
9
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global
burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat
Rev Gastroenterol Hepatol. 2018;15(1):11-20.
10
Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a
metabolic disease in humans: A literature review. Diabetes Obes Metab.
2021;23(5):1069-83.
11
Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, et al. Glucagonlike peptide 1 (GLP-1). Mol Metab. 2019;30:72-130.
12
Targher G, Mantovani A, Byrne CD. Mechanisms and possible hepatoprotective
effects of glucagon-like peptide-1 receptor agonists and other incretin receptor
12